Business Wire

TX-ASCEND-PERFORMANCE

15.6.2020 21:13:10 CEST | Business Wire | Press release

Share
Ascend Launches Acteev Protect™ Antimicrobial Technology

Ascend Performance Materials has introduced Acteev Protect™, a breakthrough technology specially formulated to guard against the growth of mildew, fungi and other microbes to keep textiles and nonwoven fabrics fresher for longer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005732/en/

The technology is a leap forward in protection for face masks, apparel, upholstery, air filters and more, said Lu Zhang, Ph.D., Ascend’s vice president leading the Acteev launch. “Bacteria, mildew and other microbes growing on fabrics and filters cause the item to break down, discolor and give off unpleasant smells,” she said. “Acteev Protect guards against that microbial growth, keeping the articles clean.”

The technology has been in development for several years, but with the recent shortage of articles resistant to microbial growth, Ascend accelerated the product launch by partnering with independent labs for testing and reallocating resources to scale up production. “The current global scarcity of microbe-resistant materials is not going to end unless manufacturers are able to obtain the right media,” Dr. Zhang said. “We saw a way we could quickly meet those urgent needs with this innovative technology.”

Acteev Protect combines zinc ion technology with polyamide-based woven, nonwoven and knit fabrics. The active zinc ions are embedded into the polymer matrix, providing a long-lasting solution that does not wash away, unlike topical finishes or coatings. The polyamide fabrics are durable yet soft to the skin, and the nonwoven filtration media – available as nanofibers, meltblown and spunbond – efficiently keep out unwanted particles.

The embedded zinc in its ionic form is a powerful inhibitor of bacterial growth, said Vikram Gopal, Ph.D., Ascend’s senior vice president of technology. “Zinc is an essential element needed for bacterial growth, so bacteria readily allows it inside the cell body. But the zinc ion outcompetes other essential elements such as manganese and magnesium and chokes their ingestion channels,” he said. “Without those minerals, the microbes can’t grow or reproduce.”

Other products use silver as an antimicrobial, Dr. Gopal said, but that metal comes with unwanted environmental consequences. “Silver is typically used as a finish or a coating,” he said. “That process is water-intensive, and the excess silver has to be disposed of, eventually ending up in our waterways.”

Zinc, however, is labeled Generally Regarded as Safe by the U.S. Food and Drug Administration.

Additionally, the fabrics feature all the benefits of premium polyamides, which offer more comfort than polypropylene in single-use masks and allows knits and wovens to be dyed, printed on and laundered.

Polyamide 66 wovens and knits have considerable advantages over other types of nylons in garments and other textile applications, said Harrie Schoots, president-elect of the American Association of Textile Chemists and Colorists and a senior business leader of Ascend’s textile business.

“This material resists abrasion and doesn’t pill or shed microfibers. It has a soft hand and excellent drape, and it can be dyed solid or bright colors,” Schoots said. “Uniforms or activewear made with Acteev Protect will be durable and comfortable and can be designed to match current color trends.”

Additionally, these features will last the lifetime of the garment. “Because the zinc ions are embedded during the polymerization process, knit and woven articles made with Acteev Protect stand up to 50 washes or more,” Schoots said.

Ascend is the world’s largest fully integrated producer of polyamide 66 resins and also manufactures fibers and chemicals. Acteev Protect is the company’s first product offering available in ready-to-use fabric form factors. The company plans to extend the line in the coming months to include polyamide 66 fabrics for medical applications and engineered plastics for high-touch surfaces.

For more information, to request a sample or to see performance data, please visit ascendmaterials.com/acteevprotect .

Acteev Protect does not protect users or others against disease-causing bacteria.

About Ascend Performance Materials

Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has nine global locations, including five fully-integrated manufacturing facilities located in the southeastern United States and an engineering plastics compounding facility in Europe, all dedicated to the innovation and safe production. With three of the world’s largest chemical processing facilities, Ascend’s materials form the building blocks for products used in everyday applications from apparel to airbags, cable ties to circuit boards and carpets to car parts. Ascend’s 2,600-person global workforce is committed to making a difference in the communities we serve and leading the development of material solutions that inspire everyone, everywhere, every day.

Together, we’re making a difference.
Together, we’re inspiring everyday.

More information about Ascend can be found at www.ascendmaterials.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye